TGF-β Modulates ovarian cancer invasion by upregulating CAF-Derived versican in the tumor microenvironment

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5016-5028

  Yeung, Tsz Lun ^a   Leung, Cecilia S ^a,b   Wong, Kwong Kwok ^a,b   Samimi, Goli ^c   Thompson, Melissa S ^a   Liu, Jinsong ^a   Zaid, Tarrik M ^a   Ghosh, Sue ^d   Birrer, Michael J ^e   Mok, Samuel C ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ST VINCENT'S CLINIC   (Australia)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR; SMAD PROTEIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; VERSICAN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER TISSUE; CARCINOMA CELL; CELL MOTILITY; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84882661249     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0023     Document Type: Article

References (35)

1. WuX, Groves FD, McLaughlin CC, Jemal A, Martin J, Chen VW. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control 2005;16:309-20.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 1999;75:72-7.
5. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res 2003;63:1413-9.
6. Sunde JS, Donninger H,WuK, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006;66:8404-12.
7. Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: Connecting TGF-beta signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle 2012;11:3019-35.
8. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS II, et al. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011; 71:1272-81.
9. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Crosstalk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007;67:4244-53.
10. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006;1:119-50.
11. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001;11:54-9.
12. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, et al. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol 2010;119:114-20.
13. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
14. Massague J, Blain SW, Lo RS. TGF beta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
15. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
16. Drabsch Y, Ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 2012;31:553-68.
17. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101:4966-71.
18. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010;17:319-32.
19. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
20. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012;481:85-9.
21. Wang Z, Ouyang G. Periostin: a bridge between cancer stem cells and their metastatic niche. Cell Stem Cell 2012;10:111-2.
22. Haleem-Smith H, Calderon R, Song Y, Tuan RS, Chen FH. Cartilage oligomeric matrix protein enhances matrix assembly during chondrogenesis of human mesenchymal stem cells. J Cell Biochem 2012; 113:1245-52.
23. Gagarina V, Carlberg AL, Pereira-Mouries L, Hall DJ. Cartilage oligomeric matrix protein protects cells against death by elevating members of the IAP family of survival proteins. J Biol Chem 2008;283:648-59.
24. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008;128:871-81.
25. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
26. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009;9:108-22.
27. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005;15:483-94.
28. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007;282: 10814-25.
29. Gardner MJ, Catterall JB, Jones LM, Turner GA. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin Exp Metastasis 1996;14:325-34.
30. Hall CL, Lange LA, Prober DA, Zhang S, Turley EA. pp60(c-src) is required for cell locomotion regulated by the hyaluronanreceptor RHAMM. Oncogene 1996;13:2213-24.
31. Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, et al. Cross-talk between TGF beta1 and EGFR signalling pathways induces TM4SF5 expression and epithelial-mesenchymal transition. Biochem J 2012; 443:691-700.
32. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005;16:1330-40.
33. Ellenrieder V. TGFb regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer. Anticancer Res 2008;28: 1531-9.
34. Jungert K, Buck A, Buchholz M, Wagner M, Adler G, Gress TM, et al. Smad-Sp1 complexes mediate TGFb-induced early transcription of oncogenic Smad7 in pancreatic cancer cells. Carcinogenesis 2006;27:2392-401.
35. Li JM, Datto MB, Shen X, Hu PP, Yu Y, Wang XF. Sp1, but not Sp3, functions to mediate promoter activation by TGF-b through canonical Sp1 binding sites. Nucleic Acids Res 1998;26: 2449-56.